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HPC1/RNASEL was recently identified as a candidate gene for hereditary prostate cancer. We identified a novel
founder frameshift mutation in RNASEL, 471delAAAG, in Ashkenazi Jews. The mutation frequency in the Ash-
kenazi population, estimated on the basis of the frequency in 150 healthy young women, was 4% (95% confidence
interval [CI] 1.9%–8.4%). Among Ashkenazi Jews, the mutation frequency was higher in patients with prostate
cancer (PRCA) than in elderly male control individuals (6.9% vs. 2.4%; odds ratio p 3.0; 95% CI 0.6–15.3;
). 471delAAAG was not detected in the 134 non-Ashkenazi patients with PRCA and control individualsPp .17
tested. The median age at PRCA diagnosis did not differ significantly between the Ashkenazi carriers and noncarriers
included in our study. However, carriers received diagnoses at a significantly earlier age, compared with patients
with PRCA who were registered in the Israeli National Cancer Registry (65 vs. 74.4 years, respectively; ).P ! .001
When we examined two brothers with PRCA, we found a heterozygous 471delAAAG mutation in one and a
homozygous mutation in the other. Loss of heterozygosity was demonstrated in the tumor of the heterozygous sib.
Taken together, these data suggest that the 471delAAAG null mutation is associated with PRCA in Ashkenazi men.
However, additional studies are required to determine whether this mutation confers increased risk for PRCA in
this population.
Prostate cancer (PRCA), like other common forms of can-
cer, has a hereditary component. Linkage analysis iden-
tified several chromosomal loci that may harbor PRCA-
susceptibility genes (Smith et al. 1996; Berthon et al. 1998;
Xu et al. 1998; Berry et al. 2000; Ostrander and Stanford
2000; Tavtigian et al. 2001). Mutations in these genes are
estimated to cause ∼9% of all PRCA cases (Carter et
al. 1992). TheHPC1/RNASEL gene (MIM 180435) on
chromosome 1q25 was recently identified, and germline
mutations in this gene cosegregated with the disease in
two families showing linkage with HPC1 (Carpten et al.
2002). One of the RNASEL mutations, E265X, was also
associated with hereditary prostate cancer (HPC) in Finn-
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ish patients (Rokman et al. 2002). RNASEL encodes the
2′,5′-oligoisoadenylate-synthetase–dependent ribonucle-
ase L protein (RNASEL), which regulates cell prolifera-
tion and apoptosis through the interferon-regulated 2-5A
pathway (Zhou et al. 1993). It has been suggested to be
a tumor suppressor gene (Carpten et al. 2002).
Unlike breast, ovarian, and colon cancers (Struewing
et al. 1995; Laken et al. 1997), very little is known about
susceptibility genes for prostate cancer in Jewish men.
To examine the role of RNASEL in PRCA among Jews,
we first analyzed the entire coding sequence of the gene
through use of RNA extracted from blood leukocytes
of two Ashkenazi sib pairs affected with PRCA. This
was performed using RT-PCR followed by denaturing
high-performance liquid chromatography (DHPLC) and
sequencing analysis. We identified a novel, 4-bp deletion
mutation, 471delAAAG, in one sib pair (fig. 1). The
mutation, at codon 157 in exon 1, results in a premature
truncation at codon 164. In this sib pair, one brother,
who received a diagnosis at age 65 years, was hetero-
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Figure 1 Detection of the RNASEL 471delAAAG frameshift
mutation by sequencing (A–C) and DHPLC (D–F) analyses. A–C, The
AAAG deleted sequence is marked by a box; the deletion site is in-
dicated by an arrow. A and D, unaffected control individual. B and
E, PRCA-affected individual heterozygous for the 471delAAAG
mutation. C and F, PRCA-affected individual homozygous for the
471delAAAG mutation.
zygous for the mutation (fig. 1B and 1E), whereas the
other, who received a diagnosis at age 57 years, was
homozygous for this mutation (fig. 1C and 1F).
We further analyzed DNA samples from a microdis-
sected tumor and a benign prostatic hyperplasia (BPH)
of the brother who had the heterozygous 471delAAAG
mutation. DHPLC analysis demonstrated loss of hetero-
zygosity (LOH) in the tumor DNA, whereas heterozy-
gosity was maintained in the BPH sample. Sequencing
confirmed the sole presence of the 471delAAAG allele
in the tumor DNA. This finding is in agreement with
the results of Carpten et al. (2002), who showed LOH
of the wild-type allele and absence of RNASEL protein
in tumor cells from a patient with HPC carrying the
E265Xmutation. Taken together, these observations fur-
ther support the important role of RNASEL in prostate
cancer pathogenesis.
To assess the frequency of 471delAAAG among Jewish
patients with PRCA and the control population, we an-
alyzed DNA from an additional 119 unselected patients
(85 Ashkenazi and 34 non-Ashkenazi) and from 333 con-
trol individuals (233 Ashkenazi and 100 non-Ashkenazi).
These DNA samples were obtained from patients who
received diagnoses during the years 1991–1997 in two
different medical centers in Israel (Hubert et al. 1999).
The median age at the time of diagnosis, for all patients
and for the subgroup of Ashkenazi patients, was 68 years
(range 48–80 years). Two control groups were studied:
the first consisted of elderly Ashkenazi Jewish men with
no personal history of cancer ( ; median age 74np 83
years, range 59–92 years). These were recruited on the
basis of a self-administrated questionnaire in which they
indicated no history of cancer, including prostate cancer.
They were not screened for PRCA by either a prostate-
specific antigen blood test or a medical examination. The
second control group included healthy young Jewish
women, aged 20–45 years (150 Ashkenazi and 100 non-
Ashkenazi). The non-Ashkenazi female control group
consisted of four distinct ethnic groups, originating from
northern Africa, Iran/Iraq, the Balkans, and Yemen (25
individuals from each group). All participating subjects
signed written informed consent and identified themselves
as either Ashkenazi or non-Ashkenazi Jews of a particu-
lar ethnic origin. DNA samples were blinded and tested
anonymously.
The exon 1 fragment containing the 471delAAAGmu-
tation (bases 286–667 of RNASEL) was amplified, and
the 382-bp PCR products were analyzed by the WAVE
DHPLC apparatus (Transgenomics), under conditions de-
scribed elsewhere (Gavert et al. 2002). The primer se-
quences were as follows: forward primer, 5′ TTT ATC
CTC GCA GCG ATT G 3′; and reverse primer, 5′ GCG
TAA TAG CCT CCA CAT CAC 3′. Because the DHPLC
profiles of the homozygous wild-type and mutant alleles
were similar (fig. 1D and 1F), mixing studies were per-
Reports 983
Table 1
Frequency of the RNASEL 471delAAAG Mutation in
Unselected Patients with PRCA and Control Individuals,
Stratified by Ethnic Origin
Study Group
No.
Tested
No. of
Carriers (%)a
Ashkenazi Jews:
Patients with PRCA 87 6 (6.9)b
Elderly male control individuals 83 2 (2.4)
Young female control individuals 150 6 (4.0)
Total 320 14
Non-Ashkenazi Jews:
Patients with PRCA 34 0
Young female control individuals 100 0
Total 134 0
a Ashkenazi patients with PRCA versus elderly male control
individuals: (95% CI 0.6–15.3; ). YoungORp 3.0 Pp .17
Ashkenazi female control individuals (95% CI 1.9%–8.4%)
versus non-Ashkenazi young female control individuals: P !
..05
b A homozygous sib was not included.
formed to identify 471delAAAG homozygotes. All ab-
normal DHPLC profiles were confirmed by sequence
analysis on the initial PCRproduct and on an independent
PCR, using an automated ABI Prism 310 Genetic Ana-
lyzer (Perkin ElmerApplied Biosystems).Nodiscrepancies
between DHPLC results and sequencing were detected.
Statistical analyses were performed using SPSS Base 11.0
and EpiInfo 2000 software. The mutation frequency in
the Ashkenazi population was estimated using the young
Ashkenazi female control group as a point in a binomial
distribution. Upper and lower percentage pointswere then
calculated as the limits of the CI around it. The odds ratio
(OR) and CI were calculated as an estimation of risk
among mutation carriers. x2 and Fisher exact tests were
used, when appropriate, to determine significant differ-
ences in mutation and marker frequencies. Statistical dif-
ferences in age at diagnosis of PRCAwere calculatedusing
the median test.
Table 1 presents the frequencies of the 471delAAAG
mutation in the different study groups. The estimation of
the mutation frequency in the Ashkenazi Jewish popu-
lation was calculated on the basis of the frequency among
150 young female control individuals, because women
are not at risk for PRCA. In this group, the mutation
frequency was 4% (95%CI 1.9%–8.4%), comparedwith
0% in the non-Ashkenazi female control group (P !
). To determine the mutation frequency among Ash-.05
kenazi patients with PRCA,we included only onemember
affected with prostate cancer per family, on the basis of
“first sample obtained.” Among Ashkenazi patients with
PRCA, 471delAAAG was found in 6.9% (6/87), com-
pared with 2.4% (2/83) among elderly Ashkenazi male
control individuals ( ; 95% CI 0.6–15.3;ORp 3.0 Pp
). Of the 87 Ashkenazi patients with PRCA, 7 had a.17
first-degree relative affected with PRCA, 2 (28.6%) of
whom carried the mutation ( ; 95% CI 1.9–ORp 16.2
140.2; ). Finally, the mutation was not de-Pp .029
tected in any of the 34 non-Ashkenazi patients with
PRCA.
Rokman et al. (2002) noted that an earlier age of PRCA
diagnosis (∼11 years) was associated with the RNASEL
E265X mutation in patients from Finnish families with
HPC. In our group of Ashkenazi patients with PRCA,
there was a small, nonsignificant difference in the median
age at diagnosis between 471delAAAG carriers and non-
carriers (65 vs. 68.5 years, respectively). However, the
median ages at diagnosis for carrier and noncarrier pa-
tients with PRCA in the study were 9.4 and 5.9 years
earlier, respectively, compared with all 4,866 Ashkenazi
patients with PRCA registered in the Israel National Can-
cer Registry (INCR) in the years 1991–1997 (74.4 years;
) (INCR Web site).P ! .001
To determine whether 471delAAAG is a founder mu-
tation, we performed genotyping using two closely
linked markers, D1S2818 and D1S158 (NCBI Web site),
flanking the RNASEL gene (∼2 Mb apart). This analysis
revealed that the patient homozygous for 471delAAAG
was also homozygous for D1S2818 and D1S158 alleles,
containing 22- and 15-dinucleotide repeats, respectively.
Moreover, this D1S281822/D1S15815 haplotype was
present in 100% (15/15) of 471delAAAG carriers, com-
pared with only 32.5% (13/43) of noncarrier Ashkenazi
patients with PRCA ( ). These data suggest thatP ! .001
471delAAAG is a founder mutation in the Ashkenazi
Jewish population.
Interestingly, we found the 471delAAAG mutation in
LNCaP cells, one of the most commonly used human
PRCA cell lines, but not in two other PRCA cell lines,
PC3 and DU145. LNCaP cells originated from a lym-
phatic metastasis of a prostatic adenocarcinoma in a
50-year-old white male (Horoszewicz et al. 1980). The
LNCaP cells, however, did not carry the commonly
linked D1S15822 allele. This finding could be explained
by the many rearrangements that occurred in these cells
during repeated passages, or by de novo occurrence of
471delAAAG in either the LNCaP cells or in other non-
Jewish white populations.
The 471delAAAG is the first founder null mutation
in a known HPC gene that is potentially associatedwith
an increased risk of PRCA in Ashkenazi Jewish men.
Since our preliminary results regarding this risk are not
statistically significant, additional population-based
studies are required to determine whether there is an
age-specific PRCA risk conferred by heterozygous or
homozygous 471delAAAG mutations. Further studies
are also needed to determine whether this relatively
common mutation in Ashkenazi Jews is also associated
with familial clustering of PRCA or with other cancer
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types, as well as to verify the clinical value of genetic
screening for this mutation.
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